

**REQUEST****FOR****CONTINUED EXAMINATION (RCE)  
TRANSMITTAL**

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995.  
See the American Inventors Protection Act of 1999 (AIPA).

Application Number	09/314,161
Filing Date	May 19, 1999
First Named Inventor	M. EISENBACH-SCHWARTZ
Group Art Unit	1647
Examiner Name	S. Turner
Attorney Docket Number	EIS-SCHWARTZ=2

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

**NOTE:** 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53(d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Final Rule, 65 Fed. Reg. 50092 (Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000) 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 2000), which established RCE practice.

**RECEIVED**

JAN 03 2003

TECH CENTER 1600/2900

12/31/2002 HDEHESS1 00000083 09314161

01 FC:2801

370.00 OP

1. **Submission required under 37 C.F.R. § 1.114**

- a. ☐ Previously submitted
- i. ☐ Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on \_\_\_\_\_  
(Any unentered amendment(s) referred to above will be entered)
- ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_
- iii. ☐ Other \_\_\_\_\_
- b. ☒ Enclosed
- i. ☒ Amendment/Reply
- ii. ☒ Affidavit(s)/Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)
- iv. ☐ Other \_\_\_\_\_

2. **Miscellaneous**

- a. ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required).
- b. ☐ Other \_\_\_\_\_

3. **Fees**

The RCE fee under 37 C.F.R. § 1.17(e) is required by 37 C.F.R. § 1.114 when RCE is filed.

- a. ☒ For:
- i. ☒ RCE fee required under 37 C.F.R. § 1.17(e)
- ii. ☒ Extension of time fee (37 C.F.R. §§ 1.136 and 1.17) (☐ \$ \_\_\_\_\_ already paid for \_\_\_\_\_ month(s) extension of time on \_\_\_\_\_)
- iii. ☐ Other \_\_\_\_\_
- b. ☒ Payment by:
- i. ☐ Check in the amount of \$ \_\_\_\_\_ enclosed (Check No. \_\_\_\_\_)
- ii. ☒ Credit card (Form PTO-2038 enclosed) authorized in the amount of \$ 570.00
- iii. ☐ Charge \$ \_\_\_\_\_ to Deposit Account No. 02-4035
- c. ☒ Provisional extension of time if needed. Applicants authorize any charge of additional fees (except issue fee) which may be required in connection with this application to Deposit Account No. 02-4035.
- d. ☒ The director is hereby authorized to charge any underpayment of fees, or credit any overpayments, to Deposit Account No. 02-4035

**SIGNATURE OF APPLICANT, ATTORNEY, AGENT REQUIRED**

Name (Print/Type)	Roger L. Browdy	Registration No. (Attorney/Agent)	25,618
Signature	<i>Roger L. Browdy</i>	Date	December 30, 2002

**CERTIFICATE OF MAILING OR TRANSMISSION**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on:

Name (Print/Type)		Registration No. (Attorney/Agent)	
Signature		Date	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, DC 20231.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: EIS-SCHWARTZ=

In re Application of:	)	Conf. No.: 4767
	)	
EISENBACH-SCHWARTZ et al	)	Art Unit: 1647
	)	
Appln. No.: 09/314,161	)	Examiner: S. Turner
	)	
Filed: May 19, 1999	)	Washington, D.C.
	)	
For: ACTIVATED T-CELLS, NERVOUS)	)	December 30, 2002
SYSTEM-SPECIFIC ANTIGENS )		
AND THEIR USES )		

TECH CENTER 1600/2800

JAN 03 2003

RECEIVED

20/B  
A.g.w.  
1/7/03

12/31/2002 HDEHESS1 00000083 09314161

02 FC:2252

200.00 OP

AMENDMENT

Honorable Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action of July 30, 2002,  
petition for a two-month extension of time and payment being  
attached hereto, please amend as follows:

IN THE CLAIMS

Delete claims 17, 18 and 20-37 without prejudice  
toward the continuation of prosecution thereof in one or more  
divisional applications.

Rewrite claim 1 in amended form as follows:

Claims 1-15, 19, and 38 have been amended as follows:

1 (Twice-amended). A method for reducing neuronal  
degeneration in the central nervous system or peripheral  
nervous system of an individual suffering from an injury or

B<sup>1</sup>